Pharma & Digital Health News — Week of Feb 16, 2026
Major Deals & Partnerships
- BMS × Evinova: AI-native Study Designer for global clinical development optimization
- BMS × Microsoft: FDA-cleared radiology AI (Precision Imaging Network) for lung cancer detection
- Viseven × drcom: Personalized pharma communications across APAC
Market Data
- Drug discovery tech market: $77.6B (2026), projected ~$150B by 2032
- AI-native platforms identified as primary growth driver
- Ecosystem density and measurable partnership activity replacing broad awareness strategies
Upcoming Events
- HLTH Europe: June 15-18, Amsterdam — key for cross-border pharma/digital health dealmaking
- Focus on: payer/provider/pharma/vendor convergence, platform consolidation
Ada Health Competitive Landscape
Active pharma partnerships: Takeda, Sanofi, Alnylam, Novartis, Bayer, Pfizer
No new 2026 pharma deals announced — potential whitespace for new entrants
Implications for Daniel
- AI-native clinical tools are mainstream (BMS deploying globally) — validates the market
- Pharma buyers increasingly want measurable partnership outcomes, not pilots-for-PR
- HLTH Europe could be strategic for European pharma connections (RRW angle)